Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.
Renault AL, Mebirouk N, Cavaciuti E, Le Gal D, Lecarpentier J, d'Enghien CD, Laugé A, Dondon MG, Labbé M, Lesca G, Leroux D, Gladieff L, Adenis C, Faivre L, Gilbert-Dussardier B, Lortholary A, Fricker JP, Dahan K, Bay JO, Longy M, Buecher B, Janin N, Zattara H, Berthet P, Combès A, Coupier I; CoF-AT study collaborators; Hall J, Stoppa-Lyonnet D, Andrieu N, Lesueur F. Renault AL, et al. Among authors: bay jo. Carcinogenesis. 2017 Oct 1;38(10):994-1003. doi: 10.1093/carcin/bgx074. Carcinogenesis. 2017. PMID: 28981872 Free PMC article.
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab; Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F. Renault AL, et al. Among authors: bay jo. Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9. Breast Cancer Res. 2018. PMID: 29665859 Free PMC article.
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.
Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F. Moeung S, et al. Among authors: bay jo. Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569. Ther Drug Monit. 2019. PMID: 30299429
Telomere status in chronic lymphocytic leukemia with TP53 disruption.
Guièze R, Pages M, Véronèse L, Combes P, Lemal R, Gay-Bellile M, Chauvet M, Callanan M, Kwiatkowski F, Pereira B, Vago P, Bay JO, Tournilhac O, Tchirkov A. Guièze R, et al. Among authors: bay jo. Oncotarget. 2016 Aug 30;7(35):56976-56985. doi: 10.18632/oncotarget.10927. Oncotarget. 2016. PMID: 27486974 Free PMC article.
Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P, Labopin M, Socie G, Rubio MT, Blaise D, Vigouroux S, Huynh A, Michallet M, Bay JO, Maury S, Yakoub-Agha I, Fegueux N, Deconinck E, Contentin N, Maillard N, Bulabois CE, Francois S, Oumedaly R, Raus N, Mohty M. Chevallier P, et al. Among authors: bay jo. Eur J Haematol. 2015 May;94(5):449-55. doi: 10.1111/ejh.12451. Epub 2014 Oct 13. Eur J Haematol. 2015. PMID: 25238651
[Virus and cancer: Still hot topic].
L'Allemain G, Bay JO, Dutreix M, Vignot S. L'Allemain G, et al. Among authors: bay jo. Bull Cancer. 2018 Feb;105(2):133-134. doi: 10.1016/j.bulcan.2018.01.007. Bull Cancer. 2018. PMID: 29477229 French. No abstract available.
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B; French Immunotherapy Intergroup. Negrier S, et al. Among authors: bay jo. Cancer. 2007 Dec 1;110(11):2468-77. doi: 10.1002/cncr.23056. Cancer. 2007. PMID: 17932908 Free article. Clinical Trial.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Escudier B, et al. Among authors: bay jo. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7. Lancet. 2007. PMID: 18156031 Clinical Trial.
379 results